Pharmacokinetics of a Transdermal Testosterone System in Men with End Stage Renal Disease Receiving Maintenance Hemodialysis and Healthy Hypogonadal Men
Atam B. Singh, Keith Norris, Nishit Modi, Indrani Sinha-Hikim, Ruoquing Shen, Tina Davidson and Shalender Bhasin
Divisions of Endocrinology, Metabolism, and Molecular Medicine (A.B.S., I.S.-H., R.S., T.D., S.B.) and Nephrology and Hypertension (K.N.), Charles R. Drew University of Medicine and Science, Los Angeles, California 90059; and Alza Corporation (N.M.), Mountain View, California 94043
Address correspondence and requests for reprints to: Shalender Bhasin, M.D., Professor of Medicine, UCLA School of Medicine, Chief, Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California 90059.
Abstract
Androgen deficiency is common in men with end stage renal disease (ESRD) on maintenance hemodialysis. Pharmacokinetics of transdermal testosterone in men receiving maintenance hemodialysis have not been studied.
Our objective was to compare the pharmacokinetics of a transdermal testosterone system in healthy hypogonadal men and in men with ESRD on maintenance hemodialysis.
We recruited 10 healthy hypogonadal men and 8 medically stable men on maintenance hemodialysis, 18&endash;70 yr old, who had serum testosterone less than 300 ng/dL. After baseline sampling during a 24-h control period, two testosterone patches were applied daily for 28 days, to achieve a nominal delivery of 10-mg testosterone daily. In addition to single, pooled samples on days 7, 14, and 21, blood was drawn at 0, 2, 4, 6, 8, and 24 h on day 28 in healthy hypogonadal men and on an interdialytic day (day 21 or 28) as well as a dialysis day (day 21 or 28) in men on hemodialysis. On the dialysis day (day 21 or 28), serum free and total testosterone levels were measured hourly for 4 h before hemodialysis and for 4 h during hemodialysis. The dialysate was sampled for testosterone measurement.
Baseline mean SD total (92 ± 82 vs. 222 ± 50 ng/dL) and free (11 ± 9 vs. 27 ± 6 pg/mL) testosterone concentrations were lower in healthy hypogonadal men than in men with ESRD. After application of two testosterone patches, serum total and free testosterone concentrations rose into the midnormal range in both groups of men. Time-average, steady state (total testosterone, 506 ± 88 vs. 516 ± 86 ng/dL; free testosterone, 55 ± 9 vs. 67 ± 11 pg/mL), minimum, and maximum total and free testosterone concentrations were not significantly different between the two groups of men during treatment. Increments in total and free testosterone concentrations above baseline, baseline-subtracted areas under the total and free testosterone curves, and half-life of testosterone elimination (t1/2, 2.1 ± 0.1 vs. 2.1 ± 0.2 h, P = not significant) were not significantly different between the two groups. In men receiving hemodialysis, time-average, steady state, and maximal total and free testosterone concentrations and baseline-subtracted areas under the total and free testosterone curves were higher on dialysis day than on an interdialytic day. On the day of hemodialysis, time-average total and free testosterone concentrations were not significantly different during the 4 h before or during hemodialysis. The amount of testosterone removed in the dialysate (8.4 ± 1.6 µg during 4 h of hemodialysis) was small compared with the daily testosterone production rates in healthy young men. Serum dihydrotestosterone and estradiol concentrations increased into the normal male range and were not significantly different between the two groups. Percent suppression of LH was greater in men with ESRD than in healthy hypogonadal men.
A regimen of two Testoderm TTS testosterone patches (Alza Corp., Mountain View, CA) daily can maintain serum concentrations of total and free testosterone and its metabolites dihydrotestosterone and estradiol in the midnormal range in healthy hypogonadal men and men on hemodialysis. The amount of testosterone cleared by hemodialysis is small, and hemodialysis does not significantly affect serum total and free testosterone concentrations in men treated with the testosterone patch.
Health Headlines MORE »
Capsaicin (found in hot peppers) and capsiates (present in sweet peppers) exert modest weight management benefits.
While over 20% of U.S. adults receive periodic health examinations each year, many do not receive recommended preventive screening tests and counseling services
Researchers from Norway suggest a mechanism by which stress may make a person fat, and being obese may create stress.
Swedish researchers report that people who are short on sleep experience greater levels of hunger.
Among women with Generalized Anxiety Disorder (GAD), regular physical activity helps to reduce anxiety, irritability, feelings of tension, low energy and pain.
For every 100 mg per-day increase in magnesium in the diet, stroke risk may decline by up to 9%.
The best male marathon runners over age 65, and the best female marathon runners over age 45, continue to consistently improve their performance.
UCLA-led team safely uses human embryonic stem cells to treat macular degeneration.
First-of-its-kind study reports that indoor air in offices is an important source of worker exposure to potentially toxic substances.
Twenty percent of Americans ages 18+ experienced a diagnosable mental, behavioral, or emotional disorder in 2010.
